| | | Morningstar Overall Rating: |  | | Total Assets: | 302.35M | | Category: | Health | | Total Expense Ratio: | % |
|
| PERFORMANCE & RISK | 30-Nov-09 |
| YTD Return: | 8.58% | | 5y Avg Return: | 2.34% | | Rank in Category (ytd): | 143 | | % Rank in Category (ytd): | 86.67% | | Beta (3y): | 0.58 | | Morningstar Risk Rating: | Above average |
|
| The investment seeks capital appreciation. The fund normally invests at least 80% of net assets in securities of biotechnology companies and discovery research firms. It may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion, and may invest a small portion of assets in private or illiquid securities, such as late stage venture capital financings. The fund may also invest up to 20% of net assets in equity or debt securities of any type of foreign or U.S. issuer. It is nondiversified. | | | Fund Profile |
|
Help
0.49 (0.83%) 
Summary
Add FBDIX to Portfolio 
Download Data
